Hansoh Pharma (03692) announced that on November 12, 2026, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorisation for aumolertinib for the treatment of non-small cell lung cancer.